Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-17253.33%
operating margin TTM
-19160.0%
revenue TTM
8.79 Million
revenue per share TTM
0.13$
valuation ratios | |
|---|---|
| pe ratio | -7.64 |
| peg ratio | 0.50 |
| price to book ratio | 3.75 |
| price to sales ratio | 1,317.69 |
| enterprise value multiple | -7.20 |
| price fair value | 3.75 |
profitability ratios | |
|---|---|
| gross profit margin | 100.0% |
| operating profit margin | -19160.0% |
| pretax profit margin | -17253.33% |
| net profit margin | -17253.33% |
| return on assets | -44.39% |
| return on equity | -41.68% |
| return on capital employed | -54.02% |
liquidity ratios | |
|---|---|
| current ratio | 10.49 |
| quick ratio | 10.49 |
| cash ratio | 0.57 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 490.32 |
| days of payables outstanding | 0.00 |
| cash conversion cycle | 490.32 |
| receivables turnover | 0.74 |
| payables turnover | 0.00 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.00 |
| debt equity ratio | 0.00 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.00 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -90.30 |
cash flow ratios | |
|---|---|
| free cash flow per share | -3.21 |
| cash per share | 7.80 |
| operating cash flow per share | -3.17 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | -90.30 |
| short term coverage ratios | -135.92 |
| capital expenditure coverage ratio | -86.95 |
Frequently Asked Questions
When was the last time Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported earnings?
Celldex Therapeutics, Inc. (CLDX) published its most recent earnings results on 10-11-2025.
What is Celldex Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Celldex Therapeutics, Inc. (NASDAQ:CLDX)'s trailing twelve months ROE is -41.68%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Celldex Therapeutics, Inc. (CLDX) currently has a ROA of -44.39%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did CLDX's net profit margin stand at?
CLDX reported a profit margin of -17253.33% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is CLDX's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 10.49 in the most recent quarter. The quick ratio stood at 10.49, with a Debt/Eq ratio of 0.00.